NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's Lymphoma

NCT01684865

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Non-Hodgkin's Lymphoma

Interventions: Rituximab

Countries: North Macedonia

This prospective observational study will evaluate the safety and efficacy of first-line rituximab maintenance therapy in participants with follicular non-Hodgkin's lymphoma. Participants initiated on rituximab maintenance therapy according to the standard of care and in line with the current summary of product characteristics will be followed for a maximum of 3 years or until disease progression occurs.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Histological diagnosis of follicular non-Hodgkin's lymphoma
* Complete or partial response to first-line induction therapy with chemotherapy with rituximab
* Participants about to receive first-line rituximab maintenance treatment for follicular non-Hodgkin's lymphoma according to the local label

Exclusion Criteria:

* Pregnant or lactating women
* Receipt of an investigational drug within 30 days prior to initiation of observational drug
* Any medical or psychological alteration that, to criterion of the investigator, can jeopardize the capacity of the participant to grant informed consent
* Central nervous system involvement
* Hepatitis B or C virus infection or human immunodeficiency virus infection

Locations (1)

Skopje, North Macedonia